These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 28418664)

  • 1. Selective I
    Gunaga P; Lloyd J; Mummadi S; Banerjee A; Dhondi NK; Hennan J; Subray V; Jayaram R; Rajugowda N; Umamaheshwar Reddy K; Kumaraguru D; Mandal U; Beldona D; Adisechen AK; Yadav N; Warrier J; Johnson JA; Sale H; Putlur SP; Saxena A; Chimalakonda A; Mandlekar S; Conder M; Xing D; Gupta AK; Gupta A; Rampulla R; Mathur A; Levesque P; Wexler RR; Finlay HJ
    J Med Chem; 2017 May; 60(9):3795-3803. PubMed ID: 28418664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potassium Channel Blockade Enhances Atrial Fibrillation-Selective Antiarrhythmic Effects of Optimized State-Dependent Sodium Channel Blockade.
    Aguilar M; Xiong F; Qi XY; Comtois P; Nattel S
    Circulation; 2015 Dec; 132(23):2203-11. PubMed ID: 26499964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 5-Phenyl-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine as a Potent I Kur Inhibitor.
    Finlay HJ; Johnson JA; Lloyd JL; Jiang J; Neels J; Gunaga P; Banerjee A; Dhondi N; Chimalakonda A; Mandlekar S; Conder ML; Sale H; Xing D; Levesque P; Wexler RR
    ACS Med Chem Lett; 2016 Sep; 7(9):831-4. PubMed ID: 27660686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lactam sulfonamides as potent inhibitors of the Kv1.5 potassium ion channel.
    Olsson RI; Jacobson I; Iliefski T; Boström J; Davidsson Ö; Fjellström O; Björe A; Olsson C; Sundell J; Gran U; Gyll J; Malmberg J; Hidestål O; Emtenäs H; Svensson T; Yuan ZQ; Strandlund G; Åstrand A; Lindhardt E; Linhardt G; Forsström E; Högberg Å; Persson F; Andersson B; Rönnborg A; Löfberg B
    Bioorg Med Chem Lett; 2014 Mar; 24(5):1269-73. PubMed ID: 24513046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Too little, too late: chasing atrial fibrillation with sodium channel antagonists.
    Anderson ME
    J Cardiovasc Electrophysiol; 2006 Jun; 17(6):655-6. PubMed ID: 16836717
    [No Abstract]   [Full Text] [Related]  

  • 6. Discovery of ((S)-5-(methoxymethyl)-7-(1-methyl-1H-indol-2-yl)-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl)((S)-2-(3-methylisoxazol-5-yl)pyrrolidin-1-yl)methanone as a potent and selective I(Kur) inhibitor.
    Finlay HJ; Lloyd J; Vaccaro W; Kover A; Yan L; Bhave G; Prol J; Huynh T; Bhandaru R; Caringal Y; DiMarco J; Gan J; Harper T; Huang C; Conder ML; Sun H; Levesque P; Blanar M; Atwal K; Wexler R
    J Med Chem; 2012 Apr; 55(7):3036-48. PubMed ID: 22409629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benzopyran sulfonamides as KV1.5 potassium channel blockers.
    Lloyd J; Atwal KS; Finlay HJ; Nyman M; Huynh T; Bhandaru R; Kover A; Schmidt J; Vaccaro W; Conder ML; Jenkins-West T; Levesque P
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3271-5. PubMed ID: 17462888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks K(v)1.5 channels, for the potential treatment of atrial fibrillation.
    Billman GE
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1048-58. PubMed ID: 20730700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent antagonists of the Kv1.5 potassium channel: synthesis and evaluation of analogous N,N-diisopropyl-2-(pyridine-3-yl)acetamides.
    Nanda KK; Nolt MB; Cato MJ; Kane SA; Kiss L; Spencer RH; Wang J; Lynch JJ; Regan CP; Stump GL; Li B; White R; Yeh S; Bogusky MJ; Bilodeau MT; Dinsmore CJ; Lindsley CW; Hartman GD; Wolkenberg SE; Trotter BW
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5897-901. PubMed ID: 16949818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Smoothing the Bumpy Road to Antiarrhythmic Drug Development.
    Robinson VM; Kowey PR
    Circulation; 2015 Dec; 132(23):2195-7. PubMed ID: 26499961
    [No Abstract]   [Full Text] [Related]  

  • 11. Design of Conformationally Constrained Acyl Sulfonamide Isosteres: Identification of N-([1,2,4]Triazolo[4,3- a]pyridin-3-yl)methane-sulfonamides as Potent and Selective hNa
    Focken T; Chowdhury S; Zenova A; Grimwood ME; Chabot C; Sheng T; Hemeon I; Decker SM; Wilson M; Bichler P; Jia Q; Sun S; Young C; Lin S; Goodchild SJ; Shuart NG; Chang E; Xie Z; Li B; Khakh K; Bankar G; Waldbrook M; Kwan R; Nelkenbrecher K; Karimi Tari P; Chahal N; Sojo L; Robinette CL; White AD; Chen CA; Zhang Y; Pang J; Chang JH; Hackos DH; Johnson JP; Cohen CJ; Ortwine DF; Sutherlin DP; Dehnhardt CM; Safina BS
    J Med Chem; 2018 Jun; 61(11):4810-4831. PubMed ID: 29737846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of I
    Juhász V; Hornyik T; Benák A; Nagy N; Husti Z; Pap R; Sághy L; Virág L; Varró A; Baczkó I
    Can J Physiol Pharmacol; 2018 Jan; 96(1):18-25. PubMed ID: 28892643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atrial fibrillation: Therapeutic potential of atrial K
    Ravens U; Odening KE
    Pharmacol Ther; 2017 Aug; 176():13-21. PubMed ID: 27742566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RSD-1235. Cardiome.
    Billman GE
    Curr Opin Investig Drugs; 2003 Mar; 4(3):352-4. PubMed ID: 12735238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kv1.5 is an important component of repolarizing K+ current in canine atrial myocytes.
    Fedida D; Eldstrom J; Hesketh JC; Lamorgese M; Castel L; Steele DF; Van Wagoner DR
    Circ Res; 2003 Oct; 93(8):744-51. PubMed ID: 14500335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quinazolin-4-piperidin-4-methyl sulfamide PC-1 inhibitors: alleviating hERG interactions through structure based design.
    Patel SD; Habeski WM; Cheng AC; de la Cruz E; Loh C; Kablaoui NM
    Bioorg Med Chem Lett; 2009 Jun; 19(12):3339-43. PubMed ID: 19435660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B.
    Zhang N; Zhang X; Zhu J; Turpoff A; Chen G; Morrill C; Huang S; Lennox W; Kakarla R; Liu R; Li C; Ren H; Almstead N; Venkatraman S; Njoroge FG; Gu Z; Clausen V; Graci J; Jung SP; Zheng Y; Colacino JM; Lahser F; Sheedy J; Mollin A; Weetall M; Nomeir A; Karp GM
    J Med Chem; 2014 Mar; 57(5):2121-35. PubMed ID: 24266880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of small-conductance Ca2+-activated K+ channels terminates and protects against atrial fibrillation.
    Diness JG; Sørensen US; Nissen JD; Al-Shahib B; Jespersen T; Grunnet M; Hansen RS
    Circ Arrhythm Electrophysiol; 2010 Aug; 3(4):380-90. PubMed ID: 20562443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial-selective K
    Ravens U
    Can J Physiol Pharmacol; 2017 Nov; 95(11):1313-1318. PubMed ID: 28738160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a highly selective acetylcholine-activated K+ channel blocker on experimental atrial fibrillation.
    Machida T; Hashimoto N; Kuwahara I; Ogino Y; Matsuura J; Yamamoto W; Itano Y; Zamma A; Matsumoto R; Kamon J; Kobayashi T; Ishiwata N; Yamashita T; Ogura T; Nakaya H
    Circ Arrhythm Electrophysiol; 2011 Feb; 4(1):94-102. PubMed ID: 21156770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.